-1
archive,category,category-life-sciences-healthcare,category-97,strata-core-1.1.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.4,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-7.4,vc_responsive

Life Sciences & Healthcare

Oxford-based Mirobio raises £80 million to help treat autoimmune diseases

MiroBio, the Oxford University spin-out which is learning the language of immune cells to control their activity, is developing checkpoint agonists (agonists activate pathways that promote adaptive immune responses) to treat autoimmune diseases. It has has now completed a $97 million (£80 million) Series B financing led by...

Life Sciences boom continues at Harwell Campus as Vaccitech joins

As pandemic life sciences boom sees unprecedented demand for flexible space, Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company, responsible for the technology behind the Oxford/AstraZeneca vaccine, has taken 31,000 sq. ft within the Zeus development at Harwell Science and Innovation Campus, as active enquiries...

Life Sciences boom at Harwell Campus

In just five years, the HealthTec Cluster at Harwell Science and Innovation Campus has tripled in size, creating more than 700 new jobs. The network of life sciences-focused businesses, academia and national research infrastructure (STFC) led by a dedicated Science and Technology Facilities (STFC) team...